Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions Save this search Download search results Subscribe to news feed Your filters: cql: author="Gatell, JM" or (type any "bookEditor issueEditor" and editor="Gatell, JM") Add to list Journal Article A1 Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years : final 96-week results of the NEAT022 study JM Gatell, L Assoumou, G Moyle, L Waters, M Johnson, P Domingo, J Fox, E Martinez, HJ Stellbrink, G Guaraldi, et al. (2019) CLINICAL INFECTIOUS DISEASES. 68(4). p.597-606 Add to list Journal Article A1 open access Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 Joseph J Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A Post, Stéphane De Wit, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, et al. (2019) ANTIVIRAL RESEARCH. 170.